{"id":255,"date":"2024-10-17T10:00:00","date_gmt":"2024-10-17T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=255"},"modified":"2025-09-08T09:21:27","modified_gmt":"2025-09-08T09:21:27","slug":"china-bd-2024-chengdu-baiyu-and-novartis-enters-a-1-17-billion-usd-license-on-small-molecule-anti-tumor-asset","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/255.html","title":{"rendered":"[China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor asset"},"content":{"rendered":"\n<p>Announced Date: 2024-10-16 (October 16, 2024)<\/p>\n\n\n\n<p>Asset Name: Undisclosed<\/p>\n\n\n\n<p>Licensor (Seller): Chengdu Baiyu Pharmaceutical\u00a0 (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Novartis<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: Undisclosed<\/p>\n\n\n\n<p>Current Stage: Undisclosed<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Baiyu will receive <\/p>\n\n\n\n<p>Upfront payment of $70 million,<\/p>\n\n\n\n<p>Development, regulatory and commercial milestones payments of up to $1.1 billion.<\/p>\n\n\n\n<p>Tiered royalties.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/en.baiyu.cn\/gsxw\/160.html\">Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor-Chengdu Baiyu Pharmaceutical Co., Ltd.<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Chengdu Baiyu, \u6210\u90fd\u767e\u88d5<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-10-16 (October 16, 2024) Asset Name: Undisclosed Licensor (Seller): Chengdu Baiyu Pharmaceutical\u00a0 (China) Licensee &hellip; <a title=\"[China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor asset\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/255.html\"><span class=\"screen-reader-text\">[China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor asset<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-255","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=255"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/255\/revisions"}],"predecessor-version":[{"id":256,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/255\/revisions\/256"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}